Chinese biopharmaceutical firm Innovent Biologics and Japan's Takeda Pharmaceutical have signed a license agreement worth up to $11.4 billion (approximately ¥1.75 trillion), marking one of the largest out-licensing deals ever by a Chinese drugmaker. The partnership centers on next-generation antibody drugs, including a PD-1/IL-2 bispecific antibody and antibody-drug conjugates (ADCs), and adopts a co-development and co-commercialization model that splits costs and profits. For overseas chemical and pharmaceutical supply-chain players, this signals a major shift in how Chinese innovators are entering global markets, potentially reshaping sourcing and partnership dynamics for active pharmaceutical ingredients (APIs) and intermediates.
Deal structure and financial terms
Under the agreement, Takeda will pay an upfront fee of $1.2 billion (about ¥180 billion), including $100 million (¥15.3 billion) allocated as an equity investment in Innovent. Additional milestone payments could reach up to $10.2 billion (¥1.57 trillion) based on development and commercial progress. This is the second-largest licensing deal globally, trailing only the $22 billion ADC deal between Daiichi Sankyo and AstraZeneca in 2023.
Co-development and co-commercialization model
Unlike traditional one-time license transfers, the 'Co-Co model' requires Innovent and Takeda to jointly fund development and share future profits. Takeda obtains rights to markets outside China, Hong Kong, Macau, and Taiwan. In the U.S., costs and profits will be split 60:40 (Takeda:Innovent). This model is typically reserved for blockbuster drugs with potential annual sales exceeding $1 billion.
Key drug candidates and clinical potential
The deal covers IBI363, a PD-1/IL-2 bispecific antibody that is the first to enter Phase III trials globally, and IBI343, an ADC. IBI363 targets lung cancer, colorectal cancer, and other solid tumors, showing promise in PD-1-resistant and cold-tumor patients. Phase I/II data presented at ASCO 2024 demonstrated a median overall survival of 16.1 months in advanced colorectal cancer patients, surpassing standard care. A third early-stage bispecific ADC, IBI3001, is included as an option for Takeda.
What buyers should watch
For chemical suppliers of pharmaceutical intermediates, APIs, and excipients, this deal signals growing demand for high-quality raw materials to support global clinical trials and eventual commercialization of novel biologics. The Co-Co model may encourage more Chinese biotechs to seek international partners, increasing sourcing opportunities for specialty chemicals used in ADC payloads, linkers, and monoclonal antibody production. Importers and distributors should monitor regulatory developments in the U.S. and Japan, as well as potential trade policy shifts under the Trump administration that could affect cross-border drug development.
China sourcing context
Innovent's ambition to evolve from a domestic biotech into a global pharma player reflects a broader trend among Chinese drugmakers. The deal underscores China's growing capability in innovative drug discovery, particularly in immuno-oncology and ADCs. For overseas chemical buyers, this means a more mature and competitive Chinese supply base for high-value pharmaceutical intermediates and custom synthesis services. However, geopolitical risks and export controls remain factors to watch.
Source: Read the original report | Published: November 05, 2025